Related Experiment Video
Updated: Oct 1, 2025
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
14.6K
Role of Virus-Directed Therapy in Soft Tissue Sarcoma
Hira Chaudhary1, Sandra D'Angelo2
1Department of Sarcoma, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering, 1275 York Ave, New York, NY, 10065, USA.
Current Treatment Options in Oncology
|March 8, 2022
Summary
Oncolytic viruses (OVs) show promise as immunotherapy for rare bone and soft tissue sarcomas. Combining OVs with other therapies may improve treatment efficacy for these diverse cancers.
Area of Science:
- Oncology
- Immunotherapy
- Virology
Background:
- Bone and soft tissue sarcomas are rare, heterogeneous cancers with poor response to conventional chemotherapy.
- A significant unmet need exists for novel therapeutic strategies in sarcoma treatment.
- Recent advances in sarcoma treatment emphasize histology-specific approaches based on tumor biology.
Purpose of the Study:
- To review clinical data on oncolytic viruses (OVs) as an immunotherapy for soft tissue sarcoma (STS) and bone sarcomas.
- To highlight the potential of OVs in addressing the heterogeneity of sarcoma.
- To explore combination strategies to enhance OV efficacy in sarcoma treatment.
Main Methods:
- Review of collective clinical data on oncolytic virus therapy in sarcoma.
- Analysis of OV application in soft tissue sarcoma (STS) and bone sarcomas.
- Exploration of potential combination therapies with OVs.
Main Results:
- Oncolytic viruses (OVs) have demonstrated encouraging results in treating various solid tumors, including sarcomas.
- The heterogeneity of sarcoma necessitates tailored immunotherapy approaches, aligning with OV potential.
- Preliminary data suggests OVs are a promising immunotherapy option for soft tissue and bone sarcomas.
Conclusions:
- Oncolytic viruses represent a promising immunotherapy avenue for soft tissue and bone sarcomas.
- Combining OVs with T cell-activating checkpoint inhibition, adoptive cell therapy, or targeted therapies may enhance antitumor efficacy.
- Further research and clinical trial design focusing on histology-specific approaches are crucial for optimizing OV-based sarcoma treatment.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
5.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.5K
01:27Tumor Immunotherapy
708
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
708
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:29Subviral Agents
157
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
157